d-alpha tocopherol has been researched along with cabergoline in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Ahlskog, JE; Kokmen, E; Low, PA; Nickander, KK; Petersen, RC; Tyce, GM; Uitti, RJ | 1 |
| Okamoto, K; Sohmiya, M; Suzuki, Y; Tanaka, M; Yoshida, T | 1 |
| Battaglia, A; Canonico, PL; Francioli, E; Lombardi, G; Miglio, G; Varsaldi, F | 1 |
| Fujisawa, A; Okamoto, K; Sohmiya, M; Tanaka, M; Yamamoto, Y | 1 |
1 review(s) available for d-alpha tocopherol and cabergoline
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
4 other study(ies) available for d-alpha tocopherol and cabergoline
| Article | Year |
|---|---|
No evidence for systemic oxidant stress in Parkinson's or Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Antiparkinson Agents; Brain; Cabergoline; Carbidopa; Diabetes Mellitus; Ergolines; Female; Free Radicals; Humans; Levodopa; Lipid Peroxidation; Male; Malondialdehyde; Oxidative Stress; Parkinson Disease; Selegiline; Vitamin E | 1995 |
Antioxidant properties of cabergoline: inhibition of brain auto-oxidation and superoxide anion production of microglial cells in rats.
Topics: Animals; Animals, Newborn; Antioxidants; Brain; Cabergoline; Cells, Cultured; Dose-Response Relationship, Drug; Ergolines; Male; Microglia; Oxidation-Reduction; Rats; Rats, Wistar; Superoxides; Vitamin E | 2002 |
Cabergoline protects SH-SY5Y neuronal cells in an in vitro model of ischemia.
Topics: Animals; Antioxidants; Cabergoline; Cell Death; Cell Hypoxia; Cell Line, Transformed; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Ergolines; Free Radical Scavengers; Free Radicals; Gene Expression; Genes, bcl-2; Glucose; Haloperidol; Humans; Ischemia; Neurons; Thiobarbituric Acid Reactive Substances; Time Factors; Tretinoin; Vitamin E | 2004 |
Synergistic inhibition of lipid peroxidation by vitamin E and a dopamine agonist, cabergoline.
Topics: Antioxidants; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Synergism; Ergolines; In Vitro Techniques; Kinetics; Lipid Peroxidation; Liposomes; Time Factors; Vitamin E | 2004 |